Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine, Cisplatin, and Erlotinib in HCC and BTC
NCT00832637Phase 2Terminated
- Sponsor
- New Mexico Cancer Research Alliance
- Start
- Aug 2007
- Primary completion
- Jun 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of erlotinib in hepatocellular carcinoma (HCC), biliary tract cancer (BTC), sponsored by New Mexico Cancer Research Alliance. Started Aug 2007; status: terminated.
02
Drugs
erlotinib
03
Conditions
hepatocellular carcinoma (HCC)biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT00832637.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00832637.